NICE Bites – Cerebral palsy in under 25’s

NICE Bites – Cerebral palsy in under 25’s NICE Bites No 97 May 2017 includes one topic: Cerebral palsy in […]

Cold Chain Guidance 2017

The cold chain guidance for immunisation providers commissioned by NHS England Cumbria and North East Region has been reviewed and updated. The guidance first issued in 2015 now includes more advice relating to temperature monitoring, especially the use of data loggers. It also contains a key points section at the beginning which can be used as an aid memoire. However, please ensure that all staff responsible for cold chain maintenance are familiar with the whole document.

MHRA Drug Safety Update May 2017

MHRA Drug Safety Update May 2017 A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (vol 10, […]

NICE Bites – Managing medicines for adults receiving social care in the community

NICE Bites – Managing medicines for adults receiving social care in the community NICE Bites April 2017; No 96 includes […]

NICE issues updated clinical guideline for the management of type 2 diabetes mellitus (NG28)

The updated guideline now includes text on sodium–glucose cotransporter 2 (SGLT-2) inhibitors in the section on initial drug treatment. Additionally, new information on SGLT-2 inhibitors was added to the box on action to take if metformin is contraindicated or not tolerated.

NICE Bites – Spondyloarthritis

NICE Bites – Spondyloarthritis NICE Bites March 2017; No 95 includes one topic, Spondyloarthritis in over 16’s: diagnosis and management. […]

Medicines Q&A: Can tricyclic antidepressants cause tinnitus?

Medicines Q&A: Can tricyclic antidepressants cause tinnitus? This Medicines Q&A from UK Medicines Information evaluates the limited published evidence available […]

Nystatin dose update: 1ml QDS

The British National Formulary (BNF) has updated the dosage recommendations for nystatin suspension for the treatment of oral candidiasis, to reflect the Summary of Product Characteristics (SPC) for GENERIC nystatin products.

The BNF dosage recommendation has reverted back to the lower dose (in the generic SPC), and is as follows:
Adults and children — 100,000 units (1 ml) 4 times a day.

MHRA Drug Safety Update April 2017

Valproate and developmental disorders: new alert asking for patient review and further consideration of risk minimisation measures

Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction

Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy

Letters sent to healthcare professionals in March 2017: Nulojix (belatacept) 250 mg: supply shortage—restricted to existing patients